Zoetis unveils a cutting-edge Monoclonal Antibodies (mAbs) expansion facility in Nebraska to address osteoarthritis pain in pets
Biotech Corporate

Zoetis Unveils Monoclonal Antibodies Expansion in Lincoln, NE

Zoetis has officially inaugurated its groundbreaking Monoclonal Antibodies (mAbs) expansion facility in Lincoln, Nebraska. The company’s commitment to innovation, quality, and the welfare of animals is reflected in this state-of-the-art facility that promises to revolutionize the treatment of osteoarthritis pain in dogs and cats.

The inauguration ceremony, graced by local dignitaries including U.S. Senator Pete Ricketts and Lincoln Mayor Gaylor Baird, was a celebration of Zoetis’ unwavering dedication to animal health. The event was attended by key company leaders, including Zoetis CEO Kristin Peck and Nick Ashton, President of Global Manufacturing and Supply. The opening of this new facility underscores Zoetis’ pivotal role in shaping the future of veterinary medicine and its commitment to meeting the evolving needs of pet care customers.

The expansion of the Lincoln manufacturing site marks an important milestone for Zoetis, enabling increased production of products designed to alleviate osteoarthritis pain in dogs and cats. This therapeutic area has experienced remarkable growth and is a testament to Zoetis’ dedication to addressing the most pressing needs in animal health.

Beyond its immediate impact, the new facility will be a hub for innovation. It will serve as a Veterinary Medicine Research and Development (R&D) registration facility, reflecting Zoetis’ forward-looking approach to expanding its portfolio with future breakthroughs. This move highlights the company’s commitment to pushing the boundaries of veterinary care and making cutting-edge advancements accessible to animals and their caregivers.

Zoetis’ Lincoln site stands as a linchpin within the company’s expansive supply network. Spanning an impressive 1.4 million square feet on 145 acres, the facility is a testament to Zoetis’ commitment to excellence and innovation. With nearly 950 dedicated colleagues working round the clock, the Lincoln site manufactures a staggering 1,239 finished goods or stock-keeping units (SKUs) that are distributed to more than 100 countries across the globe.

The Lincoln campus encompasses manufacturing, testing, and facility support buildings, demonstrating Zoetis’ holistic approach to animal health. Notably, the facility plays a pivotal role in producing biologics, biopharmaceuticals, and pharmaceutical products for animals, contributing significantly to the well-being of a diverse range of species.

The inauguration of this expansion facility in Lincoln is a testament to Zoetis’ long-standing legacy of commitment to animal health and welfare. The company’s presence in the Lincoln community dates back to the early 20th century, with Zoetis and its predecessors consistently contributing to the region’s economic growth and prosperity. This enduring partnership underscores Zoetis’ deep-rooted commitment to making a positive impact on animals and the communities it serves.

Chris Rasmussen, Zoetis Site Leader in Lincoln, expressed the company’s enthusiasm for the new facility, highlighting the symbiotic relationship between Zoetis and the Nebraska community. He emphasized that Zoetis’ growth and success in Lincoln, spanning over a decade, is a testament to the fundamental need to ensure the health and well-being of animals.

Kristin Peck, CEO of Zoetis, echoed this sentiment, lauding the dedication of the Lincoln team to driving innovation in animal health. She underscored the pivotal role that the new mAbs expansion will play in meeting the evolving needs of customers in the rapidly growing field of animal health.

As the world’s leading animal health company, Zoetis’ commitment to nurturing the well-being of animals and humankind is unwavering. With a diverse portfolio of medicines, vaccines, diagnostics, and technologies that make a difference in over 100 countries, Zoetis is at the forefront of transforming the field of veterinary care. The company’s pioneering spirit, exemplified by the new monoclonal antibodies expansion, reaffirms its dedication to pushing the boundaries of innovation, research, and development in animal health.

In a world where the well-being of animals is inseparable from the well-being of humanity, Zoetis stands as a beacon of progress, ensuring that animals receive the care they deserve and empowering caregivers with cutting-edge solutions. The inauguration of the mAbs expansion in Lincoln is not just a milestone for Zoetis, but a leap forward for the entire field of veterinary medicine.

Image provided by Zoetis


%d bloggers like this: